Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma

Netherlands Journal of Medicine

Volumn 64, Issue 5, 2006, Pages 141-146

  Corporaal, S ^a   Smit, W M ^a   Russel, M G V M ^a   van der Palen, J ^a   Boot, H ^b   Legdeur, M C J C ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Capecitabine; Chemotherapy; Inoperable; Metastatic oesophagogastric carcinoma

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; ESOPHAGEAL ADENOCARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; INFECTION; INOPERABLE CANCER; LEUKOPENIA; MALE; METASTASIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; PROGNOSIS; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 33646829833     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 1991;265:1287-9.
2. Schroy P. Gastric cancer: pathology, pathogenesis, and risk factors. © 2004 UpToDate® version 12.3.
3. Bonis PA, Sampliner RE. Epidemiology, pathobiology, and clinical manifestations of oesophageal cancer. © 2004 UpToDate® version 12.3.
4. Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.
5. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
6. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced oesophagogastric cancer. J Clin Oncol 1997;15:261-7.
7. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
8. Etienne MC, Bernard S, Fischel JL, et al. Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 1991;63:372-7.
9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 9989; 7:425-32.
10. Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-oesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-16.
11. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999;80:269-72.
12. Kyoto Research Group for Chemotherapy of gastric Cancer. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (CP) versus 5-fluorouracil, cisplatin, and 4′-epirubicin (FPEPIR). Anticancer Res 1992; 12:1983-8.
13. Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 1995;76:1694-9.
14. Geh JI, Glynne-Jones R, Kwok QS, et al. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol 2000;12:182-7.
15. Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized phase III trial. Ann Oncol 2003;14:1735-43.
16. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19(21):4097-106.
17. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
18. Evans TR, Pentheroudakis G, Paul J, et al. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. Ann Oncol 2002;13(9):1469-78.
19. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92(3):205-16.
20. Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000;18:2648-57.
21. Bamias A, Hill M, Cunningham D, et al. Epirubicin, Cisplatin and protracted venous infusion of 5-fluorouracil for oesophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer 1996;77:1978-85.
22. De Wit R, Herrstedt J, Rapoport B, et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4077-80.
23. Shlebak AA, Smith DB. Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol 1997;39:462-6.
24. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998;160:2021-4.
25. Liu G, Franssen E, Fitch MI, Warner E. Patients preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1994;12:14-20.
26. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002;7(4):288-323.
27. Allum W, Cunningham D, Weeden S, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial). J Clin Oncol 2003;22:249 abstr 998.